William Blair Expects Weaker Earnings for PTC Therapeutics

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities researchers at William Blair cut their Q2 2025 earnings per share (EPS) estimates for PTC Therapeutics in a report released on Monday, July 14th. William Blair analyst S. Corwin now forecasts that the biopharmaceutical company will post earnings of ($1.28) per share for the quarter, down from their prior forecast of ($1.23). The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share. William Blair also issued estimates for PTC Therapeutics' FY2026 earnings at $0.36 EPS.

A number of other equities research analysts also recently weighed in on PTCT. Cantor Fitzgerald dropped their price target on shares of PTC Therapeutics from $113.00 to $112.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Truist Financial assumed coverage on shares of PTC Therapeutics in a research report on Tuesday, June 17th. They set a "buy" rating and a $80.00 price objective for the company. Wall Street Zen downgraded shares of PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 16th. Citigroup upgraded shares of PTC Therapeutics from a "sell" rating to a "neutral" rating and lowered their price objective for the company from $50.00 to $40.00 in a research report on Wednesday, May 7th. Finally, Robert W. Baird lowered their price objective on shares of PTC Therapeutics from $70.00 to $66.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $65.00.

PTC Therapeutics Stock Performance

Shares of NASDAQ PTCT traded down $0.24 during midday trading on Wednesday, reaching $48.29. The company's stock had a trading volume of 115,635 shares, compared to its average volume of 873,231. PTC Therapeutics has a fifty-two week low of $29.02 and a fifty-two week high of $58.38. The business's 50 day moving average price is $48.76 and its two-hundred day moving average price is $48.46. The company has a market cap of $3.83 billion, a P/E ratio of 7.43 and a beta of 0.50.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $9.19. PTC Therapeutics had a net margin of 33.56% and a negative return on equity of 78.56%. The company had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $437.16 million. During the same period in the previous year, the business earned ($1.20) earnings per share. The firm's quarterly revenue was down 9.6% on a year-over-year basis.

Insider Buying and Selling at PTC Therapeutics

In other PTC Therapeutics news, CEO Matthew B. Klein sold 2,804 shares of the business's stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $48.74, for a total transaction of $136,666.96. Following the sale, the chief executive officer owned 273,234 shares of the company's stock, valued at $13,317,425.16. The trade was a 1.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Mark Elliott Boulding sold 883 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $46.02, for a total transaction of $40,635.66. Following the sale, the vice president directly owned 103,901 shares in the company, valued at $4,781,524.02. The trade was a 0.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,132 shares of company stock valued at $390,825 in the last 90 days. 5.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PTCT. Sterling Capital Management LLC increased its holdings in shares of PTC Therapeutics by 424.4% in the fourth quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 522 shares during the period. Quantbot Technologies LP grew its position in PTC Therapeutics by 545.5% in the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 551 shares in the last quarter. PNC Financial Services Group Inc. grew its position in PTC Therapeutics by 84.2% in the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 320 shares in the last quarter. GAMMA Investing LLC grew its position in PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 441 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in PTC Therapeutics in the first quarter worth $61,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.